Trial Profile
Immunogenicity and safety of Sanofi Pasteur's Avaxim 80U pediatric vaccine followed by booster dose
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2019
Price :
$35
*
At a glance
- Drugs Hepatitis A vaccine inactivated (Primary)
- Indications Hepatitis A
- Focus Pharmacodynamics
- Sponsors Sanofi; Sanofi Pasteur
- 01 Feb 2019 Results published in the Medicine
- 22 Sep 2008 Primary outcome identified as providing information concerning the immunogenicity of AVAXIM 80U Pediatric vaccine as reported by ClinicalTrials.gov.
- 22 Sep 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.